Injective jumps 27% in a day, leaving NEAR and Sei behind
INJ's surge highlights potential market shifts as ETF approvals could broaden investor access, impacting supply dynamics and valuation.
جديد على الأسواق — الأسعار، والعوائد، وmarket cap؟ نشرح كل مصطلح أثناء تصفّحك، بلغة واضحة. البيانات ذاتها، مع شرح مدمج.
أنت تعرف الأسواق. البيانات فحسب — نظيفة وسريعة ومكثفة، بدون شروحات إضافية. هذا هو العرض الافتراضي.
كل رقم على هذا الموقع متاح بصيغة JSON، مع الفترة الزمنية والمصدر المرفقَين به.
اقرأ وثائق APIInjective is a Layer 1 blockchain built specifically for decentralized finance applications, sitting within the Cosmos, Ethereum, and Solana ecosystems among others. It aims to give developers ready-made financial infrastructure modules so they can build products such as decentralized exchanges, prediction markets, and lending protocols without constructing those components from scratch. The intended users are both DeFi developers who want a purpose-built foundation and the end users of the applications built on top of it.
Injective is an interoperable chain that bridges EVM-compatible networks like Ethereum and non-EVM networks like Solana through decentralized cross-chain infrastructure, allowing assets and messages to move across ecosystems. The INJ token functions inside the network as the native asset, and because the fully diluted valuation equals the market capitalization and 100 percent of the circulating supply is already issued against a null maximum supply, there is no further scheduled token emission creating dilution. The consensus algorithm and block time are not recorded in the data held by this site.
Injective generated fees of 8,038 USD in the most recent 24-hour period, 56,253 USD over the trailing 7 days, and 234,224 USD over the trailing 30 days, which annualizes to approximately 2,849,725 USD based on that 30-day window. The take rate for the trailing 30 days is recorded at 100 percent, meaning the protocol retains all fees collected rather than distributing a portion to a separate supplier side, a point confirmed by the supply-side revenue figure of zero for the same period. Fee growth over the trailing 30 days stands at 18.54 percent. The market capitalization relative to annualized fees sits at 253.43, a ratio that simply describes the relationship between the network's current size and its recent fee output.
كُتب استنادًا إلى أرقام هذه الصفحة بواسطة نموذج لغوي بالذكاء الاصطناعي وتمّت مراجعته بمقارنته بها. لا يتضمّن أي رأي بشأن السعر.
INJ's surge highlights potential market shifts as ETF approvals could broaden investor access, impacting supply dynamics and valuation.
Injective continued its rebound on Friday, trading around $9.25 as improving momentum and declining exchange balances supported a constructive outlook.
Long-term investors will want to see prices climb past $13.575 comfortably before looking for signs of a long-term trend shift.
Injective has rallied more than 8% on October 16, reaching $9.35 as increased trading activity and renewed interest in the network's institutional developments have…
Injective records significant gains as Gulf Labs joined its institutional validators with its trading volume and open interest spiking sharply recently.